Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vaccine and product developments could boost growth for the healthcare icon.

3 Green Flags for Johnson & Johnson's Future

Johnson & Johnson's (NYSE: JNJ) coronavirus vaccine candidate could be given clearance for emergency use today, following unanimous backing by a Food and Drug Administration panel. What Happened: The FDA plans to rapidly finalize the vaccine and authorize it for emergency use.

Johnson & Johnson's Vaccine Gets Unanimous Backing Of FDA Panel, Emergency-Use Authorization Soon To Come

Johnson & Johnson board member Dr. Mark McClellan says the company expects 20 million Covid vaccine doses delivered by the end of March.

Johnson & Johnson board member says 20 million Covid vaccine doses will be delivered by the end of March

Shares of Johnson & Johnson gained 1.3% in after-hours trading on Friday after the Food and Drug Administration said it has contacted the company to say it is "rapidly" working toward issuing an emergency use authorization for J&J's COVID-19 vaccine candidate. The FDA statement was sent out Friday evening about an hour after an advisory committee voted unanimously that the benefits of the experimental vaccine outweigh the risks.

FDA tells J&J it's working on an emergency authorization for its COVID-19 vaccine

NEW BRUNSWICK, N.J., Feb. 26, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) (the Company) today announced that the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) unanimously voted to recommend Emergency Use Authorization...

Johnson & Johnson Single-Shot COVID-19 Vaccine Candidate Unanimously Recommended for Emergency Use Authorization by U.S. FDA Advisory Committee

A committee of medical experts unanimously endorsed J&J's coronavirus vaccine for emergency use in the U.S. late Friday. The news prodded JNJ stock to rise in late trading.

FDA Panel Unanimously Endorses J&J's Covid Vaccine For Emergency Use

The next step is emergency use authorization by the FDA.

FDA panel gives Johnson & Johnson one-shot COVID-19 vaccine green light

Shares of Johnson & Johnson were up 1.3% in after-hours trading on Friday after a Food and Drug Administration advisory committee vote 22-0 in favor of the regulator authorizing the company's COVID-19 vaccine candidate. The FDA is not required to follow the advice of the committee but often does.

FDA committee votes unanimously, says benefits of J&J's COVID-19 vaccine outweigh the risks

Johnson & Johnson's experimental coronavirus vaccine just passed a critical hurdle, as a group of top doctors and scientists voted unanimously to endorse the shot. The US Food and Drug Administration is now expected to authorize the vaccine to be given widely in the coming days. The FDA typically follows the panel's advice, but isn't required to do so. An emergency use authorization (EUA) would likely allow the shot to be given widely to people 18 and older.

J&J's one-dose coronavirus vaccine just won a critical thumbs-up from an FDA panel, paving the way for US authorization

The full FDA is likely to approve the Johnson & Johnson Covid vaccine as early as Saturday with distribution to the states next week.

FDA panel unanimously recommends third Covid vaccine as J&J wins key vote in path to emergency use

Vaccine, along with those from Pfizer and Moderna, should provide US with more than enough supply to vaccinate every person

Johnson & Johnson one-shot Covid vaccine gets nod from FDA advisory panel

On Friday, California Governor Gavin Newsom announced that the state will receive a large shipment of the one shot Johnson & Johnson coronavirus vaccine. “The three-week preview we that were given by the Biden Administration: 380,300 next week, the week after and the week after. So it's consistent.” said the governor. “By the way, they...

California Getting 380,000 Doses Of One-Shot Johnson & Johnson Vaccine Next Week, Says Gov. Gavin Newsom

Two people suffered severe allergic reactions shortly after getting Johnson & Johnson's Covid-19 vaccine, a J&J scientist told an FDA panel.

J&J says two people had severe allergic reactions after getting Covid vaccine

As Johnson and Johnson comes closer to releasing their first COVID-19 vaccine, here's what Q.ai has to say about the rising stock.

The FDA Medical Advisor Committee Endorses Johnson & Johnson Vaccine

The number of confirmed cases of the coronavirus-borne illness COVID-19 climbed above 113 million on Friday, amid a flurry of positive vaccine news and as a regulatory advisory committee gathered to review Johnson & Johnson's vaccine candidate for a possible emergency use authorization.

Coronavirus Update: Global COVID cases top 113 million as FDA committee meets to vote on J&J vaccine

A committee of medical experts will meet Friday to discuss Johnson & Johnson's coronavirus vaccine before voting whether to recommend its authorization. The results could spark JNJ stock.

FDA Panel To Discuss J&J's Covid Vaccine: What You Need To Know

The FDA would likely move very rapidly to issue an emergency use authorization of the vaccine once approved.

The FDA Could Approve Johnson & Johnson's Vaccine as Soon as Today

Emerson Electric

General Dynamics

Procter & Gamble

Packaging Corp of America

A word that barely has been mentioned on Wall Street over the past few years is reentering the lexicon.

Interest Rates Explode Higher: 5 Safe Dividend Stocks to Buy Now

The European Medical Agency (EMA) is reportedly set to recommend Johnson & Johnson's (NYSE: JNJ) coronavirus vaccine on March 11, according to Bloomberg. The European Commission said deliveries of the J&J shot are expected to begin in early April, thus bolstering the supplies over the second and third quarters.

Johnson & Johnson's COVID-19 Vaccine Likely To Get EU Approval Early March: Bloomberg

Novavax

Both companies tested their vaccine candidates as new variants rapidly spread.

Johnson & Johnson vs. Novavax: Which Vaccine Is Best Against New Strains?

A key FDA panel is to vote on whether to recommend J&J's Covid vaccine for emergency use, which would help pave the way for a third vaccine in the U.S.

5 things to know before key FDA panel votes on J&J's single-shot Covid vaccine today

Fidelity MSCI Consumer Discretionary ETF

First Trust Consumer Discretionary AlphaDEX Fund

Vanguard Consumer Discretionary ETF

Consumer Discretionary Select Sector SPDR Fund

The moderate improvement in consumer confidence is likely to boost the consumer discretionary sector, which attracts a major portion of consumer spending.

Will ETFs Rally as US Consumer Confidence Improves in February?

Apple

Coca-Cola

Pfizer

Walmart

These 5 stocks are great stocks to buy in any future market crash, as they all have good fundamentals and great long-term prospects. The post 5 Surefire Stocks If the Market Crashes appeared first on InvestorPlace.

5 Surefire Stocks If the Market Crashes

Hello, Yesterday was a big day in vaccine news. We learned more about how well Johnson & Johnson's vaccine works and how safe it is. And we also learned that Moderna has a plan for tackling variants. That includes a new shot it's sending to NIH for testing.

What you need to know about J&J's coronavirus vaccine

Caterpillar

Dow Inc

Goldman Sachs

Microsoft

Travelers

We have narrowed our search to seven Dow stocks with strong growth potential for 2021. These are: GS, CAT, JNJ, AAPL, MSFT, TRV and DOW.

News for Johnson & Johnson Stock (JNJ)